Cracking Cold Tumors: MiNK's Allogeneic iNKT Platform Takes on Refractory CRC

NEW YORK, NY – October 02, 2026 – The global cell therapy sector is officially entering its next evolutionary phase. For years, the industry has been dominated by autologous CAR-T treatments—therapies that are undeniably miraculous for liquid tumors, yet fundamentally constrained by bespoke manufacturing bottlenecks, complex supply chains, and limited efficacy in solid tumors. Today, MiNK Therapeutics (NASDAQ: INKT) signaled its intent to push past these historical boundaries, announcing two upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting in November.

The clinical-stage biopharmaceutical company will present new preclinical data on its allogeneic invariant natural killer T (allo-iNKT) cell therapies, agenT-797 and MiNK-215. The findings address two of the most recalcitrant challenges in modern oncology: overcoming resistance in microsatellite-stable colorectal cancer with liver metastases, and clearing senescent tumor cells that foster immunosuppressive microenvironments. For an industry in the early innings of standardizing off-the-shelf cellular medicines, MiNK's dual approach offers a critical glimpse into how next-generation platforms might finally crack the code of "cold" solid tumors.

The Liver Metastasis Challenge in Colorectal Cancer

Microsatellite-stable (MSS) colorectal cancer accounts for the vast majority—roughly 85 to 95 percent—of all colorectal cancer cases. Characterized by a low tumor mutational burden and sparse immune infiltration, MSS CRC is notoriously resistant to conventional immune checkpoint inhibitor monotherapies. When this disease metastasizes to the liver, the therapeutic hurdle becomes exponentially higher. The liver is a naturally tolerogenic organ, evolved to suppress immune responses to the constant influx of foreign antigens from the gut. Tumors exploit this local immunosuppression, creating an immunological black hole where T-cells are excluded or exhausted.

MiNK's lead off-the-shelf candidate, agenT-797, is currently being evaluated in an active Phase 2 trial at Scripps in patients with previously treated MSS metastatic colorectal cancer with liver metastases. The preclinical data heading to SITC (Poster 270) demonstrates that agenT-797 drives tumor-cell killing in human organoid models of checkpoint inhibitor-refractory CRC liver metastases. Crucially, this efficacy is shown both as a monotherapy and in combination with botensilimab and balstilimab (BOT+BAL).

The combination strategy is particularly noteworthy. Botensilimab, an Fc-enhanced anti-CTLA-4 antibody, and balstilimab, an anti-PD-1 antibody developed by Agenus, have previously demonstrated promising activity in heavily pretreated MSS mCRC. However, clinical benefits have largely been restricted to patients without active liver metastases. By introducing agenT-797—which functions as a "master regulator" combining the cytotoxic capabilities of NK cells with T-cell-like antigen recognition—MiNK aims to bridge innate and adaptive immunity. The goal is to fundamentally heat up the liver microenvironment, allowing the BOT+BAL combination to achieve the kind of systemic responses previously unseen in this specific patient population.

Cellular Senolytics: Purging the Tumor Microenvironment

Beyond direct tumor-cell killing, MiNK is pioneering a novel application of iNKT cells: senolytic oncology. Cellular senescence is a double-edged sword in cancer biology. While senescence halts the division of damaged cells, these cells do not simply disappear. Instead, they remain metabolically active, secreting a cocktail of pro-inflammatory and immunosuppressive factors—known as the senescence-associated secretory phenotype (SASP)—that can paradoxically promote tumor growth, metastasis, and resistance to therapy.

In collaboration with the laboratory of Dr. Jesús Gil at the MRC London Institute of Medical Sciences, MiNK will present data (Poster 177) demonstrating that both native agenT-797 and its engineered counterpart, MiNK-215, effectively eliminate senescent tumor cells and fibroblasts in vitro. MiNK-215 is an investigational, allogeneic CAR-iNKT cell therapy engineered to target fibroblast activation protein (FAP) expressed on stromal cells within the tumor microenvironment, while incorporating soluble IL-15 to enhance cellular persistence.

Targeting cancer-associated fibroblasts represents a paradigm shift. These stromal cells act as the architectural architects of the tumor's defensive fortress, physically and chemically blocking immune cell infiltration. By deploying an off-the-shelf CAR-iNKT therapy to selectively purge these senescent stromal cells, MiNK is not just attacking the tumor; it is dismantling the infrastructure that allows the tumor to survive. This senolytic capacity positions iNKT cells as potential remodeling agents capable of reversing disease progression and preventing post-treatment relapse.

The Allogeneic Frontier and Commercial Realities

The scientific rationale behind MiNK's platform is compelling, but the true test of any next-generation therapy lies in its commercial and manufacturing feasibility. Autologous cell therapies are plagued by vein-to-vein logistical nightmares. MiNK's allogeneic approach, derived from healthy donors and manufactured at scale in Lexington, Massachusetts, circumvents these issues. Because iNKT cells do not require HLA matching, they can be administered without the severe risk of graft-versus-host disease (GVHD), offering a true "off-the-shelf" solution.

This manufacturing prowess was recently validated on a national scale. Just days prior to the SITC announcement, MiNK revealed its agenT-797 platform was selected for the ARPA-H-funded BioStabilization Systems (BoSS) program. This initiative, backed by up to $87 million in total funding across multiple institutions, aims to develop technologies for the room-temperature storage of living cell therapies. If successful, eliminating the reliance on costly, complex cold-chain logistics would revolutionize global supply chain dynamics for advanced therapeutics, making cell therapies as accessible as traditional biologics.

However, a clear-eyed diagnosis of MiNK's competitive positioning must acknowledge its stark financial realities. Despite its scientific momentum and advanced manufacturing infrastructure, the company is navigating a tightening cash runway. As of June 30, 2026, MiNK reported cash and cash equivalents of just $8.8 million, prompting a "going concern" warning in its recent SEC filings. While the ARPA-H program provides critical long-term validation and non-dilutive support for specific technological development, it does not immediately alleviate the capital requirements necessary to push agenT-797 and MiNK-215 through late-stage clinical trials.

For MiNK Therapeutics, the upcoming SITC presentations are more than an academic exercise; they are a critical catalyst. The data must convince institutional investors and potential pharmaceutical partners that iNKT cells hold the key to unlocking refractory solid tumors. If the preclinical promise of agenT-797 in colorectal cancer and the senolytic capabilities of MiNK-215 can translate into durable clinical responses, MiNK may well redefine the standard of care. Until then, the company remains a high-stakes bellwether for the broader allogeneic cell therapy market, balancing cutting-edge immunological science against the unforgiving realities of biotechnology financing.